SMT202400065T1 - Anticorpi contro lif e relativi usi - Google Patents

Anticorpi contro lif e relativi usi

Info

Publication number
SMT202400065T1
SMT202400065T1 SM20240065T SMT202400065T SMT202400065T1 SM T202400065 T1 SMT202400065 T1 SM T202400065T1 SM 20240065 T SM20240065 T SM 20240065T SM T202400065 T SMT202400065 T SM T202400065T SM T202400065 T1 SMT202400065 T1 SM T202400065T1
Authority
SM
San Marino
Prior art keywords
antibodies against
against lif
lif
antibodies
Prior art date
Application number
SM20240065T
Other languages
English (en)
Italian (it)
Inventor
Suarez Joan Seoane
Folgueira Judit Anido
Johan Fransson
Jean-Philippe Julien
Swetha Raman
Original Assignee
Medimmune Ltd
Fundacio Privada Inst Catalana De Recerca I Estudis Avancats
Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd, Fundacio Privada Inst Catalana De Recerca I Estudis Avancats, Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron filed Critical Medimmune Ltd
Priority claimed from PCT/IB2017/001677 external-priority patent/WO2018115960A1/en
Publication of SMT202400065T1 publication Critical patent/SMT202400065T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SM20240065T 2016-12-19 2017-12-18 Anticorpi contro lif e relativi usi SMT202400065T1 (it)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16382617 2016-12-19
US201762467017P 2017-03-03 2017-03-03
EP17382683 2017-10-13
PCT/IB2017/001677 WO2018115960A1 (en) 2016-12-19 2017-12-18 Antibodies against lif and uses thereof
EP17840489.3A EP3555132B1 (en) 2016-12-19 2017-12-18 Antibodies against lif and uses thereof

Publications (1)

Publication Number Publication Date
SMT202400065T1 true SMT202400065T1 (it) 2024-03-13

Family

ID=67138942

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20240065T SMT202400065T1 (it) 2016-12-19 2017-12-18 Anticorpi contro lif e relativi usi

Country Status (24)

Country Link
US (2) US11390670B2 (enExample)
EP (2) EP4321219A3 (enExample)
JP (3) JP7100056B2 (enExample)
KR (3) KR102716931B1 (enExample)
CN (2) CN118652335A (enExample)
AU (1) AU2017381585B2 (enExample)
BR (1) BR112019012691A2 (enExample)
CA (1) CA3047528A1 (enExample)
CL (2) CL2019001717A1 (enExample)
DK (1) DK3555132T3 (enExample)
ES (1) ES2971126T3 (enExample)
FI (1) FI3555132T3 (enExample)
HR (1) HRP20240195T8 (enExample)
HU (1) HUE065241T2 (enExample)
IL (2) IL294088B2 (enExample)
LT (1) LT3555132T (enExample)
MX (2) MX2019007376A (enExample)
NZ (1) NZ755004A (enExample)
PL (1) PL3555132T3 (enExample)
RS (1) RS65187B1 (enExample)
SA (1) SA519402119B1 (enExample)
SI (1) SI3555132T1 (enExample)
SM (1) SMT202400065T1 (enExample)
ZA (1) ZA201904533B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65187B1 (sr) * 2016-12-19 2024-03-29 Medimmune Ltd Antitela na lif i njihove primene
US20210130453A1 (en) * 2018-04-12 2021-05-06 Medimmune Limited Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
EP4069736A1 (en) * 2019-12-04 2022-10-12 MedImmune Limited Antibodies against lif and uses thereof
TWI841810B (zh) 2020-01-24 2024-05-11 日商西斯美股份有限公司 提升抗體對抗原之親和性的方法及其用途
KR20230125037A (ko) 2020-12-31 2023-08-28 노나 바이오사이언시즈 (수조우) 컴퍼니 리미티드 인간 lifr 항원 결합 단백질, 이의 제조 방법, 및 이의응용
EP4337317A1 (en) * 2021-05-14 2024-03-20 Genentech, Inc. Agonists of trem2

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
AU4231393A (en) 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
WO1993023665A1 (en) 1992-05-15 1993-11-25 Re/Map Incorporated Electromagnetic shielding for a liquid conditioning device
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
ES2254564T3 (es) 1995-04-24 2006-06-16 Genentech, Inc. Uso de antagonistas de factor de inhibicion de la leucemia.
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6399857B1 (en) * 1999-09-22 2002-06-04 Paradigm Genetics, Inc. Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1497445A2 (en) 2002-04-01 2005-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1612558A1 (en) 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Method for detecting gluten
AU2006239860B2 (en) 2005-04-25 2012-01-19 Amgen Fremont Inc. Antibodies to myostatin
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
KR20090088871A (ko) 2006-10-04 2009-08-20 더 스크립스 리서치 인스티튜트 인간 메타뉴모바이러스를 중화시키는 인간 항체
CN101440128A (zh) 2007-11-21 2009-05-27 中国人民解放军第二军医大学 人脑胶质瘤中差异表达的蛋白及其用途
CA2742968C (en) * 2008-11-07 2020-06-09 Fabrus Llc Combinatorial antibody libraries and uses thereof
ES2363358B1 (es) 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
US8221753B2 (en) * 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
JP2013506686A (ja) 2009-09-30 2013-02-28 プレジデント アンド フェロウズ オブ ハーバード カレッジ オートファジー阻害遺伝子産物の変調によりオートファジーを変調する方法
WO2011057144A2 (en) 2009-11-06 2011-05-12 La Jolla Institute For Allergy And Immunology Methods for modulating lif activity, treating immune disorders and diseases, and stimulatings immune responses
CN102167742B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗her2单克隆抗体、其制备方法及用途
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
RU2708314C2 (ru) 2013-03-11 2019-12-05 Джензим Корпорейшн Гипергликозилированные связывающие полипептиды
US20140314741A1 (en) 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
EP3037434B1 (en) 2013-08-20 2018-07-18 Japan Science and Technology Agency Human antibody kappa type light chain complex-containing composition and method for producing same
US20150056195A1 (en) 2013-08-23 2015-02-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compositions and methods for inihibiting tumorigenicity of senescent cancer cells induced by chemotherapy
WO2015040243A2 (en) 2013-09-23 2015-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for targeting tumor microenvironment and for preventing metastasis
US10808026B2 (en) 2013-10-09 2020-10-20 Research Development Foundation Monoclonal Olfml-3 antibodies and uses thereof
TWI486172B (zh) 2013-11-08 2015-06-01 Univ Chang Gung 鼻咽癌治療的醫藥
EP3092253B1 (en) 2014-01-10 2021-03-17 AnaptysBio, Inc. Antibodies directed against interleukin-33 (il-33)
EP3129067B1 (en) 2014-03-19 2023-01-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
AU2015314980A1 (en) 2014-09-10 2017-03-02 The Regents Of The University Of California Targeting K-Ras-mediated signaling pathways and malignancy by anti-hLIF antibodies
EP3173483A1 (en) * 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
RS65187B1 (sr) * 2016-12-19 2024-03-29 Medimmune Ltd Antitela na lif i njihove primene
US20210130453A1 (en) * 2018-04-12 2021-05-06 Medimmune Limited Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
WO2019243898A2 (en) * 2018-06-18 2019-12-26 Mosaic Biomedicals Slu Methods for improving response to anti-lif antibody treatment in individuals with cancer

Also Published As

Publication number Publication date
EP4321219A2 (en) 2024-02-14
DK3555132T3 (da) 2024-02-05
SI3555132T1 (sl) 2024-04-30
US11390670B2 (en) 2022-07-19
CA3047528A1 (en) 2018-06-28
MX2024003178A (es) 2024-03-25
AU2017381585A1 (en) 2019-07-18
KR20230125099A (ko) 2023-08-28
EP3555132B1 (en) 2023-11-15
CN111868086B (zh) 2024-07-16
CN118652335A (zh) 2024-09-17
LT3555132T (lt) 2024-02-26
US20230042095A1 (en) 2023-02-09
PL3555132T3 (pl) 2024-04-22
ZA201904533B (en) 2024-08-28
CN111868086A (zh) 2020-10-30
IL294088B1 (en) 2023-06-01
IL267450B (en) 2022-07-01
MX2019007376A (es) 2020-02-07
KR20240149987A (ko) 2024-10-15
RS65187B1 (sr) 2024-03-29
BR112019012691A2 (pt) 2019-11-19
ES2971126T3 (es) 2024-06-03
HRP20240195T1 (hr) 2024-04-26
NZ755004A (en) 2025-08-29
JP7100056B2 (ja) 2022-07-12
JP2022130632A (ja) 2022-09-06
CL2019001717A1 (es) 2020-02-28
CL2021000950A1 (es) 2021-11-26
FI3555132T3 (fi) 2024-02-08
HUE065241T2 (hu) 2024-05-28
HRP20240195T8 (hr) 2024-05-24
IL267450A (en) 2019-08-29
IL294088A (en) 2022-08-01
EP4321219A3 (en) 2024-05-15
JP2024075682A (ja) 2024-06-04
IL294088B2 (en) 2023-10-01
KR102599557B1 (ko) 2023-11-07
EP3555132A1 (en) 2019-10-23
AU2017381585B2 (en) 2025-02-13
SA519402119B1 (ar) 2023-02-19
US20190352389A1 (en) 2019-11-21
KR102784394B1 (ko) 2025-03-19
KR102716931B1 (ko) 2024-10-15
KR20190122652A (ko) 2019-10-30
JP2020512388A (ja) 2020-04-23
JP7459173B2 (ja) 2024-04-01

Similar Documents

Publication Publication Date Title
IL290842B1 (en) Anti-CD73 antibodies and their uses
IL285375B2 (en) IL-8-binding antibodies and their uses
IL283321A (en) Antibodies against muc16 and their uses
IL280648A (en) Anti-galectin-9 antibodies and their uses
IL271477A (en) Anti-cd166 antibodies and their uses
IL266738A (en) Novel antibodies and their uses
IL264970A (en) Anti-tim-3 antibodies and their use
IL268734A (en) Anti-LAG-3 antibodies and uses thereof
IL268700A (en) Anti-PHF-tau antibodies and uses thereof
IL258284A (en) Anti-Lag 3 antibodies and their uses
SG10202109691UA (en) Anti-pacap antibodies and uses thereof
IL257263A (en) Antibodies against angptl8 and their use
ZA201901935B (en) Anti-il-33 antibodies and uses thereof
IL269134A (en) Antibodies against PAR2 and their use
IL254954B (en) Anti-pacap antibodies and their uses
IL273157A (en) Antibodies specific to AXL and their uses
IL272476A (en) Anti-Apelin antibodies and their uses
PL3292154T3 (pl) Przeciwciała przeciwko ludzkiemu HER3 i ich zastosowania
IL266082A (en) Anti-chikv antibodies and their use
IL266049A (en) Antibodies against o1 and their uses
GB201503387D0 (en) Anti-carbapenem antibodies and uses thereof
IL267450A (en) Antibodies against lif and their uses
IL264417A (en) Anti-o2 antibodies and their uses
GB201712032D0 (en) Antibodies and uses thereof
PT3555132T (pt) Anticorpos contra lif e suas utilizações